Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 7
2023 19
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy.
Brosch-Lenz J, Delker A, Völter F, Unterrainer LM, Kaiser L, Bartenstein P, Ziegler S, Rahmim A, Uribe C, Böning G. Brosch-Lenz J, et al. Among authors: unterrainer lm. J Nucl Med. 2023 May;64(5):767-774. doi: 10.2967/jnumed.122.264594. Epub 2023 Jan 19. J Nucl Med. 2023. PMID: 36657980 Free PMC article.
Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma.
Albert NL, Nelwan DV, Fleischmann DF, Quach S, von Rohr K, Kaiser L, Teske N, Unterrainer LM, Bartos LM, Ruf VC, Brendel M, Riemenschneider MJ, Wetzel C, Herms J, Rupprecht R, Thon N, Tonn JC, Belka C, Bartenstein P, von Baumgarten L, Niyazi M, Unterrainer M, Holzgreve A. Albert NL, et al. Among authors: unterrainer lm. J Nucl Med. 2023 Oct;64(10):1519-1525. doi: 10.2967/jnumed.122.265247. Epub 2023 Aug 3. J Nucl Med. 2023. PMID: 37536737 Free PMC article.
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Mehrens D, Kramer KKM, Unterrainer LM, Beyer L, Bartenstein P, Froelich MF, Tollens F, Ricke J, Rübenthaler J, Schmidt-Hegemann NS, Herlemann A, Unterrainer M, Kunz WG. Mehrens D, et al. Among authors: unterrainer lm. J Natl Compr Canc Netw. 2023 Jan;21(1):43-50.e2. doi: 10.6004/jnccn.2022.7070. J Natl Compr Canc Netw. 2023. PMID: 36634610
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging.
Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, Gildehaus FJ, Rumiantcev M, Resch S, Hürkamp K, Wenter V, Unterrainer LM, Bartenstein P, Ziegler SI, Beyer L, Böning G. Delker A, et al. Among authors: unterrainer lm. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1280-1290. doi: 10.1007/s00259-022-06092-1. Epub 2023 Jan 11. Eur J Nucl Med Mol Imaging. 2023. PMID: 36629878 Free PMC article.
Can Radiomics Provide Additional Information in [18F]FET-Negative Gliomas?
von Rohr K, Unterrainer M, Holzgreve A, Kirchner MA, Li Z, Unterrainer LM, Suchorska B, Brendel M, Tonn JC, Bartenstein P, Ziegler S, Albert NL, Kaiser L. von Rohr K, et al. Among authors: unterrainer lm. Cancers (Basel). 2022 Oct 5;14(19):4860. doi: 10.3390/cancers14194860. Cancers (Basel). 2022. PMID: 36230783 Free PMC article.
[68Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.
Unterrainer LM, Memarzadeh S, Moatamed NA, Benz MR, Czernin J, Calais J. Unterrainer LM, et al. J Nucl Med. 2024 Jan 11:jnumed.123.266732. doi: 10.2967/jnumed.123.266732. Online ahead of print. J Nucl Med. 2024. PMID: 38212069 No abstract available.
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
Holzgreve A, Taugner J, Käsmann L, Müller P, Tufman A, Reinmuth N, Li M, Winkelmann M, Unterrainer LM, Nieto AE, Bartenstein P, Kunz WG, Ricke J, Belka C, Eze C, Unterrainer M, Manapov F. Holzgreve A, et al. Among authors: unterrainer lm. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2466-2476. doi: 10.1007/s00259-023-06192-6. Epub 2023 Mar 23. Eur J Nucl Med Mol Imaging. 2023. PMID: 36951991 Free PMC article.
Finger Pain as an Uncommon Primary Manifestation of Lung Carcinoma.
Holzgreve A, Dürr HR, Stäbler A, Kaemmerer M, Unterrainer LM, Tufman A, Manapov F, Kunz WG, Unterrainer M. Holzgreve A, et al. Among authors: unterrainer lm. Diagnostics (Basel). 2023 Feb 27;13(5):901. doi: 10.3390/diagnostics13050901. Diagnostics (Basel). 2023. PMID: 36900044 Free PMC article.
34 results